Related Experiment Video
Updated: Mar 21, 2026

Broth Microdilution In Vitro Screening: An Easy and Fast Method to Detect New Antifungal Compounds
Published on: February 14, 2018
[MIKAMINOM ANTIFUNGAL THERAPY IN NEWBORNS AND INFANTS WITH SURGICAL PATHOLOGY]
Abstract:
Prolonged empiric and etiotropic therapy of multidrug-resistant or pan-resistant bacterial flora in different gestation age newborns has led to the growth of resistant fungalflora in intencive care units (ICU). According to risk factors and rating scales every child of ICU undergoing the abdominal cavity surgery is threatened the development of a fungal infection and requires antifungal therapy appointment or causal prophylactic. In recent years, before the advent of medications of the group of echinocandins, therapy of invasive fungal infections has been a challenge. Currently alternative drug to diflucane in neonates and infants is micafungine (mycamine) in the dose of 2-8 mg/kg/day, depending on the signs of infestation and severity of the condition.
Insights
Multidrug-resistant fungal infections are increasing in neonatal intensive care units (ICUs). Micafungin offers an alternative antifungal therapy for neonates and infants at risk, especially after abdominal surgery.
Area of Science:
- Neonatal intensive care
- Infectious diseases
- Pharmacology
Background:
- Prolonged antibiotic use in neonatal intensive care units (ICUs) contributes to the rise of drug-resistant fungal infections.
- Neonates undergoing abdominal surgery face a high risk of developing fungal infections.
Purpose of the Study:
- To highlight the challenge of invasive fungal infections in neonates.
- To introduce micafungin as a viable alternative antifungal agent.
Main Methods:
- Review of current therapeutic challenges in neonatal fungal infections.
- Evaluation of micafungin as an alternative to fluconazole in neonates and infants.
Main Results:
- Micafungin is presented as an effective alternative for treating invasive fungal infections in neonates.
- Dosage recommendations for micafungin (2-8 mg/kg/day) are provided based on clinical assessment.
Conclusions:
- Micafungin represents a crucial advancement in managing fungal infections in vulnerable neonatal populations.
- Judicious use of antifungals like micafungin is essential in neonatal ICUs to combat rising resistance.
More Related Videos
06:39Author Spotlight: Exploring Photodynamic Therapy with Curcumin in a Murine Model for Oral Candidiasis
Published on: October 27, 2023
07:19A 96 Well Microtiter Plate-based Method for Monitoring Formation and Antifungal Susceptibility Testing of Candida albicans Biofilms
Published on: October 21, 2010
Related Concept Videos
Antifungal Agents
Development of the Oral Microbiota
Hand hygiene
Hand washing...
Fungal Phylum Microsporidia
Pharmacokinetics in Pediatric Patients: Drug Excretion